Comments

Y-mAbs Therapeutics Stock Guidance

YMABNASDAQ
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$5.40
-0.16-2.88%
Q4 2024 earnings tomorrow on Tue Mar 4th before the market open
Conference call scheduled tomorrow at 8:00 AM Click to view the webcast
Y-mAbs Therapeutics (YMAB) ForecastNewsEarningsY-mAbs Therapeutics (YMAB) Options

Guidance

DividendsAnalyst RatingsInsider TradesShort Interest

Y-mAbs Therapeutics Stock Guidance | NASDAQ:YMAB | Benzinga

Y-mAbs Therapeutics issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

Data brought to you by Benzinga APIs

FAQ

Q

What is the most recent guidance for Y-mAbs Therapeutics (YMAB)?

A

There have been no specific sales or earnings guidance reported for Y-mAbs Therapeutics in recent months.

Browse guidance and forecast on all stocks.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved